FDA Grants Lin BioScience Rare Pediatric Disease Status for LBS-008

"We continue to be encouraged by the regulatory support for LBS-008 and the opportunities provided by the Rare Pediatric Disease designation and the Priority Review Voucher Program," said Dr. Tom Lin, CEO of Lin Bioscience.

LBS-008 is a first-in-class oral therapy that prevents the buildup of toxins in the eye that cause Stargardt Disease and atrophic Age-related Macular Degeneration (dry AMD). The NIH's Blueprint Neurotherapeutics Network, which funded the therapy's discovery and development, provides support and funding through to the completion of Phase I clinical trials. LBS-008 received both US and EU orphan drug designation in 2017 and 2018, respectively.

-----------------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of En-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.